A Single-center, Open-Label, Exploratory Study to Assess the Tolerability and Safety of the Addition of Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With Type 1 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
Price : $35 *
At a glance
- Drugs INGAP peptide (Primary) ; Ustekinumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Proof of concept
- 31 Aug 2018 Biomarkers information updated
- 25 May 2017 Status changed from recruiting to completed.
- 28 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.